|Description||NW-457 is a potent Hsp90 inhibitor with no detectable hepatocytotoxicity in vitro. It synergizes with ionizing irradiation to induce chromatin condensation, nuclear fragmentation, apoptosis, and post-apoptotic, secondary necrosis. Enhanced apoptosis induction by NW457 in combination with irradiation is accompanied by increased caspase activation and caspase substrate cleavage.|
|Brife Description||NW-457 is a potent Hsp90 inhibitor with no detectable hepatocytotoxicity in vitro.|
|Synonyms||1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,7,8-tetrahydro-7,14,16-trihydroxy-3-methyl-, 11-[O-[2-oxo-2-(1-piperidinyl)ethyl]oxime], (3S,5E,9E,11E)-|
|Storage||3 years -20oC powder, 6 months-80oC in solvent.|
NVP-BEP800 is a novel, fully synthetic Hsp90β inhibitor with IC50 of 58 nM, exhibits >70-fold selectivity against Hsp90 family members Grp94 and Trap-1.
SST0116CL1 is a second-generation small molecule inhibitor of Hsp90, which leads to decreased expression of Hsp90 client proteins and reduced tumor cell prolife...
SNX-2112 is an Hsp90 inhibitor which is currently undergoing multiple phase 1 clinical trials. In all cell lines, SNX-2112 led to degradation of MET, HER-2, EGF...
Bnlm is a Grp94 selective inhibitors.
Chlorobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the dimerization of the Hsp90 complex.IC50 60μmol/...
Debio 0932, also known as CUDC-305, is a novel Hsp90 inhibitor with strong affinity for Hsp90 alpha/beta, high oral bioavailability and potent anti-proliferativ...
NXD30001 inhibits Hsp90, potentially resulting in decreased tumor growth.
BIIB028 blocks the binding of oncogenic client proteins to Hsp90, which may lead to the proteasomal degradation of these proteins and the inhibition of tumor ce...
PF-04929113, also known as SNX-5422; is a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although t...
BIIB021 is An orally active, purine-scaffold, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. BIIB021 that is ...
XL888 is an ATP-competitive inhibitor of Hsp90. Through this action, specific client proteins are degraded, leading to cell cycle arrest or apoptosis. XL888 is ...
CH5138303 is a novel and potent Hsp90 inhibitor. CH5138303 showed high binding affinity for N-terminal Hsp90α (Kd=0.52nM) and strong in vitro cell growth inhibi...
MPC-0767 is a novel L-alanine ester pro-drug of MPC-3100, designed to have improved aqueous solubility compared to MPC-3100.
Radester is a hybrid composed of radicicol's resorcinol and geldanamycin’s benzoquinone part structures and exhibits good cellular activity against MCF7 breast ...
DS-2248 is an orally active and small molecule inhibitor of Hsp90, with potential antineoplastic activity. Upon oral administration, Hsp90 inhibitor DS-2248 spe...
CPUY201112 is an N-terminal Hsp90 inhibitor, which leads to decreased expression of Hsp90 client proteins and may result in increased tumor cell apoptosis.
KW-2478 is an agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be ...
Ganetespib, also known as STA-9090, is a synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhib...
Onalespib, also known as AT13387, is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic a...
MPC-3100 targets the N-terminal ATP-binding site of Hsp90 and blocks the activity of ATPase. In the Her2-luciferase degradation assay, MPC-3100 reduces this cli...